40 related articles for article (PubMed ID: 31447233)
1. Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231].
Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
Lung Cancer; 2019 Dec; 138():141. PubMed ID: 31447233
[No Abstract] [Full Text] [Related]
2. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
[TBL] [Abstract][Full Text] [Related]
3. Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib.
Wang Y; Han R; Zhu M; He T; He Y
Front Oncol; 2022; 12():875313. PubMed ID: 35530305
[TBL] [Abstract][Full Text] [Related]
4. Acquired rare recurrent
Lin L; Lu Q; Cao R; Ou Q; Ma Y; Bao H; Wu X; Shao Y; Wang Z; Shen B
Am J Cancer Res; 2020; 10(11):4005-4015. PubMed ID: 33294282
[TBL] [Abstract][Full Text] [Related]
5. EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.
Kobayashi Y; Fujino T; Nishino M; Koga T; Chiba M; Sesumi Y; Ohara S; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
J Thorac Oncol; 2018 May; 13(5):727-731. PubMed ID: 29410323
[TBL] [Abstract][Full Text] [Related]
6. Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance.
Wang Z; Yang JJ; Huang J; Ye JY; Zhang XC; Tu HY; Han-Zhang H; Wu YL
J Thorac Oncol; 2017 Nov; 12(11):1723-1727. PubMed ID: 28662863
[TBL] [Abstract][Full Text] [Related]
7. Targeting EGFR
Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045.
Zhao P; Yao MY; Zhu SJ; Chen JY; Yun CH
Biochem Biophys Res Commun; 2018 Jul; 502(3):332-337. PubMed ID: 29802850
[TBL] [Abstract][Full Text] [Related]
9. Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients.
Dono M; De Luca G; Lastraioli S; Anselmi G; Dal Bello MG; Coco S; Vanni I; Grossi F; Vigani A; Genova C; Ferrarini M; Ravetti JL; Zupo S
Mol Med; 2019 Apr; 25(1):15. PubMed ID: 31029076
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into drug development strategy targeting EGFR T790M/C797S.
Zhu SJ; Zhao P; Yang J; Ma R; Yan XE; Yang SY; Yang JW; Yun CH
Oncotarget; 2018 Mar; 9(17):13652-13665. PubMed ID: 29568384
[TBL] [Abstract][Full Text] [Related]
11. Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
Hidaka N; Iwama E; Kubo N; Harada T; Miyawaki K; Tanaka K; Okamoto I; Baba E; Akashi K; Sasaki H; Nakanishi Y
Lung Cancer; 2017 Jun; 108():75-82. PubMed ID: 28625653
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.
Kim DH; Choi YJ; Kim SY; Lee JE; Sung KJ; Sung YH; Kim WS; Kim SE; Ryu HC; Kim JS; Guangying L; Choi CM; Rho JK; Lee JC
Target Oncol; 2018 Jun; 13(3):389-398. PubMed ID: 29754184
[TBL] [Abstract][Full Text] [Related]
13. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
[TBL] [Abstract][Full Text] [Related]
14. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
Patel H; Pawara R; Surana S
Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
[TBL] [Abstract][Full Text] [Related]
15. Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level.
Hammoud MK; Yosef HK; Lechtonen T; Aljakouch K; Schuler M; Alsaidi W; Daho I; Maghnouj A; Hahn S; El-Mashtoly SF; Gerwert K
Sci Rep; 2018 Oct; 8(1):15278. PubMed ID: 30323297
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.
Masuzawa K; Yasuda H; Hamamoto J; Nukaga S; Hirano T; Kawada I; Naoki K; Soejima K; Betsuyaku T
Oncotarget; 2017 Dec; 8(62):105479-105491. PubMed ID: 29285266
[TBL] [Abstract][Full Text] [Related]
17. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B
Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756
[TBL] [Abstract][Full Text] [Related]
18. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
Niederst MJ; Hu H; Mulvey HE; Lockerman EL; Garcia AR; Piotrowska Z; Sequist LV; Engelman JA
Clin Cancer Res; 2015 Sep; 21(17):3924-33. PubMed ID: 25964297
[TBL] [Abstract][Full Text] [Related]
19. Concurrent Small-Cell Transformation and Emergence of
Pizzutilo EG; Lauricella C; Cerea G; Giannetta LG; Tomasello G; Stabile S; Motta V; Alexiadis S; Scaglione F; Vanzulli A; Torre M; Bonoldi E; Veronese SM; Siena S; Sartore-Bianchi A
JCO Precis Oncol; 2019 Dec; 3():1-5. PubMed ID: 35100737
[No Abstract] [Full Text] [Related]
20. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Leonetti A; Sharma S; Minari R; Perego P; Giovannetti E; Tiseo M
Br J Cancer; 2019 Oct; 121(9):725-737. PubMed ID: 31564718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
